GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report

Article content

VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) announces that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare's newly published research report titled “New Therapies for Age-Related Skin Problems.” The report provides an in-depth analysis of the latest developments in the $12.5 billion anti-aging skin care market.

The research highlights GlycoProteMim alongside other notable active ingredients such as OneSkin's OS-01, Sisley Paris's Soy Peptides, SK-II's Pitera™, and SkinMedica's TNS Advanced Serum. GlycoProteMim is known for its unique approach to skin rejuvenation, addressing the surface appearance and underlying cellular mechanisms, making it a standout in the evolving landscape of skin care treatments.

Article content

“We are particularly excited about advanced new topics like GycoProteMim and Pitera, and peptides like OS-01 that we believe will continue to take share from the well-established retinoids, toxins, and dermal fillers market,” Stonegate Healthcare notes in its report. Research report.

Report link: Stonegate Healthcare Partners announces the publication of a thematic report on anti-aging innovations in dermatology

About Sirona Biochem

Sirona is a company specializing in the discovery of cosmetic and pharmaceutical ingredients using proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented to maximize revenue potential.

Sirona's pools are licensed to leading companies around the world in exchange for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and has received numerous French national scientific awards and EU and French government grants. For more information, please visit the website www.sironabiochem.com.

Article content

Article content

About Glycoprotimium™

GlycoProteMim, a new anti-aging complex, was developed under the supervision of Dr. Géraldine Delaincourt Godefroy, using chemistry inspired by nature. This complex has been clinically validated as a breakthrough in non-surgical anti-aging skin care, providing powerful rejuvenation to aging skin. Safe, effective and easy to use, GlycoProteMim can complement or serve as an alternative to Botox.^® and dermal fillers, depending on consumer preferences. Plans are in place to launch the first consumer product containing GlycoProteMim in Europe and North America through a subsidiary, Sirona Laboratories, in early 2025, with further expansions expected in other markets. More information can be found at https://www.glycoprotemim.com.

For more information about this press release, please contact:

Investor inquiries:

Christopher Hopton
Chief Financial Officer

Phone: (604) 641-4466
e-mail: info@sironabiochem.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Article content

Forward-looking statements

This press release includes certain statements that may be deemed “forward-looking statements.” All statements in this new release, other than statements of historical fact, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “anticipates,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” and “projects.” . Or “likely” and similar expressions, or that events or circumstances “will”, “will”, “may”, “could” or “should” occur. Although the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, the continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those anticipated in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates, opinions or other factors change.

Article content